Immunoassay Analyzers Market To Reach USD 26.40 Billion By 2027 | Reports and Data
27 août 2020 17h00 HE
|
Reports and Data
New York, Aug. 27, 2020 (GLOBE NEWSWIRE) -- The Global Immunoassay Analyzers market is forecast to reach USD 26.40 Billion by 2027, according to a new report by Reports and Data. Immunoassay...
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
07 août 2020 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
Paltusotine received Orphan Drug Designation for the treatment of acromegaly Half of the enrolled patients in the ongoing Phase 2 ACROBAT Edge clinical trial for paltusotine had completed the study...
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
17 avr. 2020 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 17, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
15 avr. 2020 00h21 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
14 avr. 2020 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
08 janv. 2020 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference
25 sept. 2019 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
03 sept. 2019 16h05 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
13 août 2019 16h14 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
29 juil. 2019 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...